TDO2 and IDO1 inhibitors

US11827639B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• NEWLINK GENETICS CORPORATION · US

Inventors

• Zhonghua Pei · South San Francisco, US
• Brendan Parr · South San Francisco, US
• Wendy Liu · Foster City, US
• Richard Pastor · South San Francisco, US
• Lewis Gazzard · Belmont, US
• Firoz Jaipuri · Bengaluru, IN
• Sanjeev Kumar · Ann Arbor, US
• Hima Potturi · Ames, US
• Guoshen Wu · Beijing, CN
• Xingyu Lin · Beijing, CN
• Yanyan Chu · Beijing, CN
• Powai Yuen · Beijing, CN

Key dates

• Filing date: Jun 28, 2018
• Grant date: Nov 28, 2023
• Expiry date: Jun 28, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Presently provided are inhibitors of TD02 and IDO1 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.